Bolt Biotherapeutics, Inc. announced the appointment of Nicole Onetto, M.D., to its Board of Directors effective Dec. 14, 2021. Dr. Onetto brings 30 years of experience primarily focused on the field of oncology at biotechnology, pharmaceutical and academic research institutions. She currently serves as an independent consultant in oncology, drug development and translational research, and on the Board of Directors at Viracta Therapeutics and Basilea Pharmaceutica. She previously served on the Board of Directors for NBE Therapeutics, Sierra Oncology, and ImmunoGen. Prior to that, Dr. Onetto held leadership roles at the Ontario Institute of Cancer Research, where she was Deputy Director and Chief Scientific Officer, and at ZymoGenetics (Bristol Myers Squibb) and OSI Pharmaceuticals (Astellas), where she held the position of Chief Medical Officer. Her career also includes senior management positions at Bristol Myers Squibb, Gilead Sciences, and Immunex Corporation (Amgen). Dr. Onetto earned her bachelor’s degree from the University of Paris, a master’s degree in Pharmacology from the University of Montréal, and her medical degree and a Hematology-Oncology Certificate from the University of Paris. In connection with Dr. Onetto’s appointment, Ashish Khanna, Ph.D., will be stepping down from Bolt Biotherapeutics’ board of directors. Dr. Khanna has served as a member of the company’s board since July 2018.